7 completed, 2 terminated. 9 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 7, Terminated 2 |
| Phase 1 | 3 | Completed 3 |
Follow Rigosertib: new trials by email Literature Review of Rigosertib trials Research Report on Rigosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors Rigosertib, Pembrolizumab, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 7 | 2023-05-09 | 2026-09-16 |
| Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment Rigosertib, Nivolumab - Non-small Cell Lung Cancer, Adenocarcinoma | Phase 1 / Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 25 | 2020-06-29 | 2024-05-09 |
| Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia Rigosertib, Questionnaire - Leukemia, Myelofibrosis | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2017-08-16 | 2020-08-07 |
| Oral Rigosertib for Squamous Cell Carcinoma rigosertib - Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma | Phase 2 | Completed | Traws Pharma, Inc. | 64 | 2013-03-01 | 2017-06-26 |
| Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome rigosertib - Myelodysplastic Syndrome, MDS | Phase 2 | Completed | Traws Pharma, Inc. | 82 | 2012-05-01 | 2017-06-26 |
| Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) rigosertib - Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Traws Pharma, Inc. | 30 | 2010-07-01 | 2017-06-26 |
| Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk ON 01910.Na - Myelodysplastic Syndrome | Phase 2 | Completed | Traws Pharma, Inc. | 14 | 2009-05-01 | 2017-06-26 |
| Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients ON 01910.Na - Ovarian Cancer | Phase 2 | Completed | Traws Pharma, Inc. | 1 | 2009-03-01 | 2017-07-21 |
| Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML ON 01910.Na - Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Traws Pharma, Inc. | 36 | 2009-01-01 | 2017-06-26 |
Myelodysplastic Syndromes (3) · Chromosome 8, trisomy (2) · Leukemia, Myeloid, Acute (2) · Primary Myelofibrosis (2) · Adenocarcinoma (1) · Anemia (1) · Anemia, Refractory (1) · Anus Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1) · Cytopenia (1) · Esophageal Squamous Cell Carcinoma (1) · Head and Neck Neoplasms (1) · Leukemia (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)
Traws Pharma, Inc. (6) · Icahn School of Medicine at Mount Sinai (1) · M.D. Anderson Cancer Center (1) · Vanderbilt-Ingram Cancer Center (1)
United States (9)
Jorge Cortes, MD (2) · Azra Raza, MD (1) · Douglas Johnson, MD (1) · Gregory P. Sutton, MD (1) · Michael Kurman, MD (1) · Peter L. Greenberg, MD (1) · Rajwanth Veluswamy, MD, MSCR (1) · Steven M. Fruchtman, MD (1)